About Associate Professor Jiajie (Jet) Hou
Group Leader, Post-treatment Cancer Immunobiology, Cancer Research Program
Associate Professor Hou was a clinician researcher and now is head of the Post-treatment Cancer Immunobiology Laboratory at QIMR Berghofer.
Associate Professor Hou obtained an MBBS (2009) and a PhD (2015) degree in China, received cancer research training from the University of Chicago and QIMR Berghofer, and practiced as a liver surgeon at Shanghai Renji Hospital and Sun Yat-sen University Cancer Centre. Before returning to QIMR Berghofer, he was an Assistant Professor of Ministry of Education Frontier Science Centre for Precision Oncology at University of Macau.
With ever-lasting interest in the field of Inflammation, Immunity and Cancer, he has published in high impact journals including Hepatology, J Hepatol, Nat Immunol, Nat Rev Clin Oncol, Cell Metab, and Nat Commun.
Now based in Brisbane, the Hou Laboratory is dedicated to understanding how therapy-induced inflammation influences anti-tumour immunity and inspires next-generation immunotherapy.
Research Skills
In the light of therapy-induced or organ-specific cues in the cancer macroenvironment, the Hou Laboraory leverages genetically modified mice and clinical samples for cellular-and-molecular immunology-based high-throughput analyses.
Thus delving into the mechanisms of how the acquired inflammation and epigenetic regulation impose therapy response or resistance.
In particular, they are looking at how post-treatment inflammation reshapes the function of anti-tumour T cells and other underrepresented immune populations, aimed to explore whether the underlying molecular traits can apply to tailoring T cell-based immunotherapy and new drug development.
Area of Interest
- T cell epigenetics and targeted cancer immunotherapy
- Post-treatment inflammation and cancer immunoediting
- Liver-specific immunity and combinatorial immunotherapy
Key Publications
Zhang H, Luo X, Yang W, Wu Z, Zhao Z, Pei X, Zhang X, Chen C, Lei J, Shi Q, Zhao Q, Chen Y, Wu W, Zeng Z, Ju H, Qiu M, Liu J, Shen B, Chen M, Chen J, Deng C, Xu R, Hou J (Senior Author). YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumor immunity. Nat Commun. 2024 Nov 5;15(1):9559
Yang Z, Wang X, Fu Y, Wu W, Hu Z, Lin Q, Peng W, Pan Y, Wang J, Chen J, Hu D, Zhou Z, Xu L, Zhang Y, Hou J (Senior Author), Chen M. YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8 T cell recruitment. Mol Cancer. 2024 Sep 6;23(1):186